We are live on ! Find out more
Cambridge Investment Research Advisors

Cambridge Investment Research Advisors Portfolio holdings

AUM $44.6B
1-Year Est. Return 28.94%
This Fund
S&P 500
This Quarter Est. Return
+3.09%
1 Year Est. Return
+28.94%
3 Year Est. Return
+82.62%
5 Year Est. Return
+90.41%
10 Year Est. Return
+293.66%
AUM
$27.1B
AUM Growth
+$1.07B
Cap. Flow
+$498M
Cap. Flow %
1.84%
Top 10 Hldgs %
21.61%
Holding
3,481
New
179
Increased
1,545
Reduced
1,498
Closed
172
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
CSBR icon
3201
Champions Oncology
CSBR
$68.8M
$63K ﹤0.01%
12,252
MIN
3202
Aberdeen Intermediate Income Fund
MIN
$281M
$62K ﹤0.01%
23,212
+3,483
+18% +$9.12K
MRDN
3203
Meridian Holdings Inc
MRDN
$178M
$60K ﹤0.01%
2,032
+214
+12% +$9.81K
CERS icon
3204
Cerus
CERS
$546M
$58K ﹤0.01%
32,810
+15,700
+92% +$28.1K
OMER icon
3205
Omeros
OMER
$992M
$58K ﹤0.01%
14,243
-500
-3% -$1.79K
AWP
3206
abrdn Global Premier Properties Fund
AWP
$362M
$57K ﹤0.01%
4,951
-223
-4% -$2.51K
SMR.WS
3207
DELISTED
NuScale Power Corporation Warrants, each exercisable for one share of Class A Common Stock at an exercise price of $11.50 per share
SMR.WS
$56K ﹤0.01%
20,000
-2,500
-11% -$3.25K
ANNX icon
3208
Annexon
ANNX
$873M
$55K ﹤0.01%
11,317
+617
+6% +$3.19K
CLNE icon
3209
Clean Energy Fuels
CLNE
$384M
$55K ﹤0.01%
20,781
+250
+1% +$644
DSX icon
3210
Diana Shipping
DSX
$296M
$55K ﹤0.01%
19,370
+25
+0.1% +$74
FUBO icon
3211
FuboTV Inc
FUBO
$293M
$54K ﹤0.01%
3,600
-361
-9% -$5.78K
NG icon
3212
NovaGold Resources
NG
$3.45B
$54K ﹤0.01%
15,483
+2,034
+15% +$6.75K
HUMA icon
3213
Humacyte
HUMA
$179M
$53K ﹤0.01%
+11,027
New +$57.4K
HRTX icon
3214
Heron Therapeutics
HRTX
$64.7M
$52K ﹤0.01%
14,867
+4,000
+37% +$12.3K
BBAI icon
3215
BigBear.ai
BBAI
$1.56B
$51K ﹤0.01%
33,777
+2,277
+7% +$3.56K
ACHR icon
3216
Archer Aviation
ACHR
$4.84B
$50K ﹤0.01%
14,167
+1,365
+11% +$5.07K
BTAI icon
3217
BioXcel Therapeutics
BTAI
$32.7M
$49K ﹤0.01%
2,378
HTZWW
3218
Hertz Global Holdings Warrants
HTZWW
$112M
$49K ﹤0.01%
19,915
ASRT
3219
DELISTED
Assertio
ASRT
$48K ﹤0.01%
2,570
-29
-1% -$431
TRIB
3220
Trinity Biotech
TRIB
$7.86M
$47K ﹤0.01%
743
ACRS icon
3221
Aclaris Therapeutics
ACRS
$860M
$46K ﹤0.01%
41,873
DHF
3222
BNY Mellon High Yield Strategies Fund
DHF
$175M
$46K ﹤0.01%
19,090
+928
+5% +$2.2K
EVGO icon
3223
EVgo
EVGO
$497M
$46K ﹤0.01%
18,611
-300
-2% -$615
HIVE
3224
HIVE Digital Technologies
HIVE
$750M
$46K ﹤0.01%
+14,905
New +$41.8K
NRO
3225
Neuberger Real Estate Securities Income Fund Inc
NRO
$188M
$45K ﹤0.01%
13,959
-6,288
-31% -$19.4K

Similar funds

Cambridge Investment Research Advisors's Q2 2024 Portfolio in Review

As of Q2 2024, Cambridge Investment Research Advisors held 3,481 positions worth $27.1B, up 4.1% from $26B the previous quarter. Its ten largest holdings account for 22% of the portfolio.

Cambridge Investment Research Advisors's Q2 2024 filing shows 179 new, 1,545 increased, 1,498 reduced and 172 closed positions. Its largest new stake was Sila Realty Trust: 733,789 shares worth $15.5M. The largest sale was Invesco QQQ Trust, an estimated $99.4M.

By sector, the portfolio is most concentrated in Technology at 12% of assets, up from 11% a quarter earlier, followed by Financials and Consumer Discretionary.

  • Cambridge Investment Research Advisors's largest Q2 2024 buy was Sila Realty Trust: 733,789 shares worth $15.5M.
  • Cambridge Investment Research Advisors added most to PIMCO Enhanced Short Maturity Active Exchange-Traded Fund in Q2 2024, an estimated $77.4M increase.
  • Cambridge Investment Research Advisors's biggest Q2 2024 reduction was Invesco QQQ Trust, cutting an estimated $99.4M.
  • Cambridge Investment Research Advisors fully exited Pioneer Natural Resource Co. in Q2 2024, selling an estimated $4.55M.
  • Cambridge Investment Research Advisors's ten largest holdings make up 22% of its $27.1B portfolio in Q2 2024.
  • Cambridge Investment Research Advisors opened 179 new positions and closed 172 in Q2 2024.
  • Cambridge Investment Research Advisors's portfolio value rose 4.1% quarter-over-quarter to $27.1B.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2024, filed 26 Jul 2024.